Lynne Sullivan - Feb 9, 2022 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Role: CFO & Head of Corp. Dev.
Signature: /s/ Alexander Nguyen, Attorney-in-Fact for Lynne Marie Sullivan
Stock symbol: UBX
Transactions as of: Feb 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/15/2022, 04:17 PM
Previous filing: Jul 30, 2021
Next filing: Mar 31, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	UBX	Common Stock, $0.0001 par value	Award	$0	+50K	+18.06%	$0.00	327K	Feb 9, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	UBX	Stock Option (Right to Buy)	Award	$0	+200K		$0.00	200K	Feb 9, 2022	Common Stock	200K	$1.06	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") one third of which vests on February 9, 2023 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F2	Includes RSUs which vest over time measured from the grant date. Also includes 5,952 shares of Common Stock of the Issuer purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
F3	The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.